NCT03564340View on ClinicalTrials.gov

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

890

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

February 1, 2026

Study Completion Date

January 31, 2027

Conditions
Recurrent Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Primary Peritoneal CancerRecurrent Endometrial CancerEndometrial CancerLow-grade Serous Ovarian Cancer
Interventions
DRUG

Ubamatamab

Administered per the protocol

DRUG

Cemiplimab

Administered per the protocol

DRUG

Sarilumab

Administered per the protocol

DRUG

Tocilizumab

Administered per the protocol

Trial Locations (52)

2650

RECRUITING

Universitair Ziekenhuis Antwerpen, Edegem

3000

RECRUITING

Peter MacCallum Cancer Center, Melbourne

RECRUITING

UZLeuven, Leuven

3080

RECRUITING

Seoul National University Hospital, Seoul

6000

RECRUITING

Grand Hopital de Charleroi, Charleroi

8908

RECRUITING

Institut Catala d'Oncologia, Barcelona

10032

RECRUITING

Columbia University Medical Center, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

14076

RECRUITING

Centre Francois Baclesse (CFB), Caen

14263

WITHDRAWN

Roswell Park Cancer Institute, Buffalo

15706

RECRUITING

Hospital Clinico Universitatio Santiago de Compostela, Santiago de Compostela

20141

RECRUITING

Istituto Europeo di Oncologia, Milan

21000

RECRUITING

Centre Georges Francois Leclerc, Dijon

23219

RECRUITING

Virginia Commonwealth University, Richmond

28027

RECRUITING

Clinica Universidad Navarra (CUN) Madrid, Madrid

28040

RECRUITING

Fundacion Jimenez Diaz, Madrid

RECRUITING

Hospital Universitario San Carlos, Madrid

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

33076

RECRUITING

Institut Bergonie, Bordeaux

35294

RECRUITING

University of Alabama_6th Ave, Birmingham

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

43026

RECRUITING

The Ohio State University Wexner Medical Center James Comprehensive Cancer Center, Hilliard

55905

RECRUITING

Mayo Clinic - Rochester, Rochester

69310

RECRUITING

Hopital Lyon Sud, Pierre-Bénite

73104

RECRUITING

Stephenson Cancer Center, Oklahoma City

80131

RECRUITING

Instituto Nazionale Tumori- Fondazione Pascale, Naples

94800

RECRUITING

Institut Gustave Roussy, Villejuif

3109601

RECRUITING

Rambam Health Care Campus, Haifa

5265601

RECRUITING

Sheba Medical Center, Tel Litwinsky

9112001

RECRUITING

Sharet Institute of Oncology, Jerusalem

02214

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Dana Farber / Harvard Cancer Center, Boston

NSW 2031

RECRUITING

Prince of Wales Hospital, Randwick

06189

RECRUITING

Centre Antoine Lacassagne, Nice

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome

6500HB

RECRUITING

Radboudumc, Nijmegen

3000 DR

RECRUITING

Erasmus MC, Rotterdam

9713 GZ

RECRUITING

University Medical Center Groningen, Groningen

03722

RECRUITING

Yonsei University Health System, Seoul

05505

RECRUITING

Asan Medical Center, Univ. of Ulsan, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

08307

RECRUITING

Korea University Guro Hospital, Seoul

08916

RECRUITING

Institut Catala dOncologia Badalona, Badalona

RECRUITING

Institut Catala d'Oncologia, Barcelona

08035

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

OX1 2JD

RECRUITING

University of Oxford, Oxford

SM2 5PT

WITHDRAWN

Royal Marsden Hospital - Sutton, Sutton

RECRUITING

The Royal Marsden NHS Foundation Trust, Sutton

NW1 2PG

RECRUITING

University College London Hospitals, London

SE1 9RT

RECRUITING

Guys Hospital, London

W12 0HS

RECRUITING

Imperial College Healthcare NHS Trust, London

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY